Sickle cell disease

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Live Alerts

PAN Foundation — Sickle cell disease status changedApply now ↗

Regulatory Watchboard

10 events
Sep 2026Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease

University Hospital, Rouen — PHASE3

TrialNOT YET RECRUITING
Apr 2026Functional Ovarian Reserve in Sickle Cell Disease

St. Jude Children's Research Hospital

TrialRECRUITING
Apr 2026Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

Emory University — PHASE4

TrialRECRUITING
Mar 2026Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care

University Hospital, Tours — NA

TrialRECRUITING
Mar 2026Open-Label Extension Study to Pioneer Study 6058-SCD-101

Fulcrum Therapeutics — PHASE2

TrialNOT YET RECRUITING
Mar 2026SickleFit Randomized Control Trial

Duke University — NA

TrialNOT YET RECRUITING
Feb 2026Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.

Assistance Publique - Hôpitaux de Paris — PHASE1, PHASE2

TrialRECRUITING
Feb 2026Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease

Mayo Clinic — NA

TrialRECRUITING
Feb 2026Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

CSL Behring — PHASE2

TrialRECRUITING
Jan 2026Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

Sanofi — PHASE3

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

26 programs

FINANCIAL LANDSCAPE SUMMARY

26

Total programs

18

Open now

7

Foundation grants

3

Copay cards

12

Travel grants

Foundation Grants7

The Assistance Fund — Sickle cell disease

The Assistance Fund

OpenContact for detailsApply ↗

Patient Services Inc — Sickle cell disease

Patient Services Inc

OpenContact for detailsApply ↗

Good Days — Sickle cell disease

Good Days

OpenContact for detailsApply ↗

HealthWell Foundation — Sickle cell disease

HealthWell Foundation

OpenContact for detailsApply ↗

NORD Patient Assistance — Sickle cell disease

NORD Patient Assistance

OpenContact for detailsApply ↗

PAN Foundation — Sickle cell disease

PAN Foundation

ClosedContact for detailsApply ↗

Patient Advocate Foundation — Sickle cell disease

Patient Advocate Foundation

OpenContact for detailsApply ↗

Copay Assistance3

Endari

Emmaus

OpenContact for detailsApply ↗

DROXIA

Bristol Myers Squibb

OpenContact for detailsApply ↗

OXBRYTA

Pfizer

OpenContact for detailsApply ↗

Patient Assistance Programs4

CASGEVY

Vertex Pharmaceuticals Incorporated

OpenContact for detailsApply ↗

ADAKVEO

Novartis Pharmaceuticals Corporation

OpenContact for detailsApply ↗

FERRIPROX

Chiesi USA, Inc.

OpenContact for detailsApply ↗

LYFGENIA

bluebird bio

OpenContact for detailsApply ↗

Travel Grants12

Bristol Myers Squibb Patient Assistance

Bristol-Myers Squibb

OpenContact for detailsApply ↗

Bristol Myers Squibb Patient Assistance Foundation Application

Bristol Myers Squibb Patient Assistance Foundation

Contact for detailsApply ↗

Bristol Myers Squibb Patient Assistance Program

Bristol-Myers Squibb

Contact for detailsApply ↗

Bristol-Myers Squibb Patient Assistance Program Application Form

Bristol-Myers Squibb

Contact for detailsApply ↗

Emmaus Life Sciences Commercial Co-Payment Assistance Program for Endari

Emmaus Life Sciences

OpenContact for detailsApply ↗

HealthWell: Sickle Cell Disease Financial Support

HealthWell Foundation

OpenContact for detailsApply ↗

Maryland Sickle Cell Disease Association Transportation Assistance Program

Maryland Sickle Cell Disease Association

Contact for detailsApply ↗

PAN: Sickle Cell Disease (Medicare)

Patient Access Network Foundation

ClosedUp to $2K/yrApply ↗

Sickle Cell Disease Financial Assistance Program

The Assistance Fund

OpenContact for detailsApply ↗

Super T's Mast Cell Foundation Patient Support Grants

Super T's Mast Cell Foundation

OpenContact for detailsApply ↗

The Assistance Fund - Sickle Cell Disease (SCD) Financial Assistance

WaitlistContact for detailsApply ↗

The Assistance Fund (TAF) Sickle Cell Disease Financial Assistance Program

The Assistance Fund

Contact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

7 FDA-approved

Lyfgenia

(LOVOTIBEGLOGENE AUTOTEMCEL)Orphan drug

Genetix Biotherapeutics Inc.

FDA label ↗

CASGEVY

(EXAGAMGLOGENE AUTOTEMCEL)Orphan drug

Vertex Pharmaceuticals Incorporated

FDA label ↗

ADAKVEO

(CRIZANLIZUMAB)Orphan drug

Novartis Pharmaceuticals Corporation

FDA label ↗

DROXIA

(HYDROXYUREA)Orphan drug

Waylis Therapeutics LLC

FDA label ↗

Endari

(GLUTAMINE)Orphan drug

Emmaus Medical, Inc.

FDA label ↗

OXBRYTA

(VOXELOTOR)Orphan drug

Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.

FDA label ↗

FERRIPROX

(DEFERIPRONE)Orphan drugstandard

Chiesi USA, Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

105 active trials
6Phase 3
3Phase 4
21Phase 2
12Phase 1
30N/A
24Unknown
7PHASE1, PHASE2
2EARLY_PHASE1
105Total recruiting
Search clinical trials for Sickle cell disease

Recent News & Research

6 articles
Pediatric blood & cancerApr 22, 2026

Clinical Practice Patterns for Discussing Hydroxyurea Initiation With Families of Children With Sickle Cell Disease.

Despite robust evidence of safety and efficacy, hydroxyurea (HU) uptake remains low for children with sickle cell disease (SCD). Guidelines recommend use of shared decision-making for HU initiation, b...

Read ↗
Journal of assisted reproduction and geneticsApr 22, 2026

Effectiveness of preimplantation genetic testing in sickle cell disease: insights from a single-center experience.

Sickle-cell disease (SCD) is a severe autosomal recessive disorder. At-risk couples may prevent transmission either through prenatal diagnosis with possible termination of pregnancy or preimplantation...

Read ↗
Journal of pediatric hematology/oncology nursingApr 20, 2026

Gene Therapy for Sickle Cell Disease.

BackgroundSickle cell disease (SCD) is a genetic blood disorder in which sickled red blood cells cannot easily pass through the vasculature, leading to impaired tissue perfusion and oxygenation that c...

Read ↗
Advanced healthcare materialsApr 17, 2026

Hemoglobin as a Molecular Glue: Toward Potent Inhibition of HbS Polymerization in Sickle Cell Disease.

Sickle cell disease (SCD), a monogenic disorder arising from a single point mutation in the β-globin gene, continues to pose a significant global health burden despite advances in supportive car...

Read ↗
Archives of biochemistry and biophysicsApr 11, 2026

Myeloperoxidase in the pathogenesis of sickle cell disease.

Sickle cell disease (SCD) is an inherited disorder characterized by abnormal hemoglobin molecules that cause the sickling of red blood cells (RBCs) which occlude blood vessels, increase hemolysis, and...

Read ↗
BloodMar 26, 2026

Benchmarking clonal hematopoiesis in sickle cell disease.

Benchmarking clonal hematopoiesis in sickle cell disease.

Read ↗

Browse all Sickle cell disease news →

Specialist Network

Top 6 by expertise

View all Sickle cell disease specialists →

Quick Actions